Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence
Authors:
- P. A. ShesternyaPSP. A. Shesternya
- A. I. ZagrebnevaAZA. I. Zagrebneva
- O. V. AntipovaOAO. V. Antipova
- Yu. V. ArbuzovaYAYu. V. Arbuzova
- I. G. BannikovaIBI. G. Bannikova
- L. V. BelozertsevaLBL. V. Belozertseva
- E. A. BogdanovaEBE. A. Bogdanova
- S. A. BykovaSBS. A. Bykova
- E. A. VasilenkoEVE. A. Vasilenko
- I. B. VinogradovaIVI. B. Vinogradova
- S. Yu. DavidyanSDS. Yu. Davidyan
- O. E. EpifanovaOEO. E. Epifanova
Open Access
- 22 April 2025
- journal article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 39-49
Abstract
Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment.Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.Keywords
This publication has 27 references indexed in Scilit:
- Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesJoint Bone Spine, 2023
- Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?BioDrugs, 2023
- Lowering Expectations: Glucocorticoid Tapering Among Veterans With Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic TherapyACR Open Rheumatology, 2023
- Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trialsZeitschrift für Rheumatologie, 2023
- Olokizumab versus Placebo or Adalimumab in Rheumatoid ArthritisNew England Journal of Medicine, 2022
- Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical TrialACR Open Rheumatology, 2020
- Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid ArthritisRheumatology and Therapy, 2020
- Validation of the Rheumatic Disease Comorbidity IndexArthritis Care & Research, 2015
- IL-6 as a keystone cytokine in health and diseaseNature Immunology, 2015
- Safety and pharmacokinetics of olokizumab, an anti‐IL‐6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I studyClinical Pharmacology in Drug Development, 2014